Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

10 May 2022: Original Paper

Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study

Bruno Roche 1BCDE , Artur Bauhofer 2ACDEF* , Miguel Ãngel Gomez Bravo 3BCDE , Georges Philippe Pageaux 4ABCDE , Fabien Zoulim 5BDE , Alejandra Otero 6BC , Martin Prieto 78BC , Carmen Baliellas 9BC , Didier Samuel 1ACDE

DOI: 10.12659/AOT.936162

Ann Transplant 2022; 27:e936162

Table 3 Post-transplant HBV recurrence and HCC recurrence.

HBV recurrenceHCC recurrence
Based on HBsAg and/or HBV DNABased on HBV DNA only
Patients, n (%)/95% CI* 7 (3.6)/1.5–7.3%1 (0.5)/0–2.8%4 (4.8)/1.3–11.9%
Annual rate2.01%0.29%2.88%
Time to event after LT [months], median (min, max)18.5 (13.1, 34.6)34.617.5 (12.5, 22.2)
* Based on all 195 patients (HBV recurrence) or 83 patients with HCC as primary indication for LT (HCC recurrence).
CI – confidence interval; HBsAg – hepatitis B surface antigen; HBV – hepatitis B virus; HCC – hepatocellular carcinoma; LT – liver transplantation.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358